doi: 10.1016/S0140-6736(03)15394-9.
Scaling-up treatment for HIV/AIDS: lessons learned from multidrug-resistant tuberculosis
Affiliations
- PMID: 14751708
- DOI: 10.1016/S0140-6736(03)15394-9
Item in Clipboard
Scaling-up treatment for HIV/AIDS: lessons learned from multidrug-resistant tuberculosis
Lancet.
.
Abstract
The UN has launched an initiative to place 3 million people in developing countries on antiretroviral AIDS treatment by end 2005 (the 3 by 5 target). Lessons for HIV/AIDS treatment scale-up emerge from recent experience with multidrug-resistant tuberculosis. Expansion of treatment for multidrug-resistant tuberculosis through the multipartner mechanism known as the Green Light Committee (GLC) has enabled gains in areas relevant to 3 by 5, including policy development, drug procurement, rational use of drugs, and the strengthening of health systems. The successes of the GLC and the obstacles it has encountered provide insights for building sustainable HIV/AIDS treatment programmes.
Similar articles
-
Scaling up HIV treatment in Peru: applying lessons from DOTS-Plus.J Int Assoc Physicians AIDS Care (Chic). 2006 Dec;5(4):137-42. doi: 10.1177/1545109706291394. J Int Assoc Physicians AIDS Care (Chic). 2006. PMID: 17101805
-
The Brazilian experiment: HIV drugs for all.J Health Care Finance. 2009 Winter;36(2):90-6. J Health Care Finance. 2009. PMID: 20499725
-
Ethical and programmatic challenges in antiretroviral scaling-up in Malawi: challenges in meeting the World Health Organization's "Treating 3 million by 2005" initiative goals.Croat Med J. 2004 Aug;45(4):415-21. Croat Med J. 2004. PMID: 15311413 Review.
-
Antiretroviral therapy in resource-poor settings: scaling up inequalities?Int J Epidemiol. 2005 Jun;34(3):509-12. doi: 10.1093/ije/dyi110. Int J Epidemiol. 2005. PMID: 15941732 No abstract available.
-
Financing of HIV/AIDS programme scale-up in low-income and middle-income countries, 2009-31.Lancet. 2010 Oct 9;376(9748):1254-60. doi: 10.1016/S0140-6736(10)61255-X. Lancet. 2010. PMID: 20934597 Review.
Cited by
-
Multidrug-resistant tuberculosis management in resource-limited settings.Emerg Infect Dis. 2006 Sep;12(9):1389-97. doi: 10.3201/eid1209.051618. Emerg Infect Dis. 2006. PMID: 17073088 Free PMC article.
-
Analysis of Green Light Committee implementation and acquisition of second-line drug resistance.Clin Infect Dis. 2015 Mar 15;60(6):970. doi: 10.1093/cid/ciu1147. Epub 2014 Dec 19. Clin Infect Dis. 2015. PMID: 25527651 Free PMC article. No abstract available.
-
HIV/AIDS epidemiology, pathogenesis, prevention, and treatment.Lancet. 2006 Aug 5;368(9534):489-504. doi: 10.1016/S0140-6736(06)69157-5. Lancet. 2006. PMID: 16890836 Free PMC article. Review.
-
Monitoring HIV treatment in developing countries.BMJ. 2006 Mar 11;332(7541):602-4. doi: 10.1136/bmj.332.7541.602. BMJ. 2006. PMID: 16528087 Free PMC article. Review.
-
Promoting development and uptake of health innovations: The Nose to Tail Tool.F1000Res. 2016 Mar 16;5:361. doi: 10.12688/f1000research.8145.1. eCollection 2016. F1000Res. 2016. PMID: 27239275 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
